LFMD - LifeMD, Inc. Stock Price, Fair Value and News

9.62USD-0.04 (-0.41%)Market Closed

Market Summary

USD9.62-0.04

Market Closed

-0.41%

LFMD Stock Price

View Fullscreen

LFMD RSI Chart

LFMD Valuation

Market Cap

388.3M

Price/Earnings (Trailing)

-19.52

Price/Sales (Trailing)

2.55

EV/EBITDA

-7.3

Price/Free Cashflow

45.07

LFMD Price/Sales (Trailing)

LFMD Profitability

Operating Margin

87.61%

EBT Margin

-29.28%

Return on Equity

-357.38%

Return on Assets

-34.01%

Free Cashflow Yield

2.22%

LFMD Fundamentals

LFMD Revenue

Revenue (TTM)

152.5M

Rev. Growth (Yr)

59.53%

Rev. Growth (Qtr)

16.18%

LFMD Earnings

Earnings (TTM)

-19.9M

Earnings Growth (Yr)

62.94%

Earnings Growth (Qtr)

27.55%

Breaking Down LFMD Revenue

Last 7 days

-3.8%

Last 30 days

-4.6%

Last 90 days

63.1%

Trailing 12 Months

505.0%

How does LFMD drawdown profile look like?

LFMD Financial Health

Current Ratio

1.22

Debt/Equity

3.38

Debt/Cashflow

0.47

LFMD Investor Care

Shares Dilution (1Y)

20.76%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	123.1M	128.6M	135.8M	152.5M
2022	103.7M	111.9M	118.3M	119.0M
2021	51.2M	64.4M	78.4M	92.9M
2020	14.1M	20.5M	28.3M	37.3M
2019	9.4M	10.1M	10.7M	12.5M
2018	4.8M	6.1M	6.6M	8.3M
2017	3.8M	3.2M	3.9M	3.3M
2016	2.6M	3.5M	4.6M	5.2M
2015	810.0K	890.7K	1.0M	1.2M
2014	770.5K	644.2K	715.0K	714.2K
2013	725.5K	820.8K	763.4K	808.4K
2012	0	0	0	673.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of LifeMD, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2024	bhatia naveen	acquired	-	-	500	-
Mar 21, 2024	yecies eric harold	acquired	-	-	56,250	general counsel & cco
Mar 21, 2024	benathen marc david	acquired	-	-	75,000	chief financial officer
Mar 21, 2024	stan maria e.	acquired	-	-	20,000	principal accounting officer
Mar 21, 2024	alvarez nicholas p	acquired	-	-	75,000	chief acquisition officer
Mar 21, 2024	galluppi stefan	acquired	-	-	30,000	chief innovation officer
Mar 13, 2024	bhatia naveen	acquired	-	-	750	-
Nov 13, 2023	schreiber justin	acquired	-	-	50,000	chief executive officer
Nov 06, 2023	jindal piyush	acquired	94,500	2.52	37,500	-
Aug 31, 2023	velge bertrand	bought	235,800	3.93	60,000	-

Which funds bought or sold LFMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 28, 2024	Newbridge Financial Services Group, Inc.	new	-	8,290	8,290	-%
Mar 11, 2024	VANGUARD GROUP INC	added	8.00	2,569,220	8,509,620	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	273,504	273,504	-%
Feb 15, 2024	State of Wyoming	new	-	137,614	137,614	0.03%
Feb 15, 2024	BARCLAYS PLC	added	116	267,000	409,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	added	845	1,711,420	1,859,650	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	149	2,165,560	3,102,160	-%
Feb 14, 2024	Graham Capital Management, L.P.	new	-	142,804	142,804	-%
Feb 14, 2024	MARSHALL WACE, LLP	reduced	-24.89	-10,187	2,668,480	-%
Feb 14, 2024	Ancora Advisors LLC	new	-	577,398	577,398	0.01%

Are Funds Buying or Selling LFMD?

Are funds buying LFMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LFMD

No. of Funds

Unveiling LifeMD, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	divisadero street capital management, lp	9.8%	3,737,685	SC 13G/A
Oct 06, 2023	divisadero street capital management, lp	5.3%	1,916,592	SC 13G

Recent SEC filings of LifeMD, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 15, 2024	S-8	Employee Benefits Plan
Mar 14, 2024	4	Insider Trading
Mar 11, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to LifeMD, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	410.7B	371.6B	-9.23%	-12.95%	18.35	1.11	14.64%	11.24%
CI	102.0B	195.3B	-0.90%	34.65%	18.99	0.52	8.17%	-20.79%
CVS	86.8B	357.8B	-10.90%	-7.68%	10.39	0.24	10.95%	93.52%
HCA	85.3B	65.0B	0.18%	18.00%	16.28	1.31	7.86%	-7.11%
CNC	38.9B	154.0B	-3.67%	6.80%	14.39	0.25	6.54%	124.79%
UHS	11.5B	14.3B	-4.30%	22.39%	16.07	0.81	6.59%	6.24%
DVA	11.4B	12.1B	-4.93%	54.73%	16.48	0.94	4.57%	23.40%
MID-CAP
CHE	9.3B	2.3B	-4.81%	9.59%	34.17	4.11	6.06%	9.17%
ACHC	6.7B	2.9B	-6.00%	-3.46%	-311.45	2.3	12.20%	-107.93%
AMEH	2.2B	1.4B	-1.50%	0.56%	35.86	1.57	21.19%	34.42%
AMN	2.2B	3.8B	-2.74%	-34.13%	10.27	0.57	-27.73%	-52.50%
SMALL-CAP
ADUS	1.6B	1.1B	0.06%	-12.91%	25.13	1.48	11.31%	35.83%
BKD	1.2B	3.0B	5.33%	55.67%	-6.33	0.4	6.74%	20.73%
BEAT	48.4M	-	-23.65%	-14.81%	-3.31	-	-	-12.94%
AMS	18.2M	21.3M	11.67%	2.14%	34.08	0.85	8.00%	-62.25%

LifeMD, Inc. News

Latest updates

LifeMD, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	16.2%	44,859,848	38,613,911	35,946,913	33,126,335	28,119,716	31,412,469	30,458,498	29,042,837	27,416,884	24,947,199	22,313,611	18,198,112	12,893,552	11,005,763	9,089,783	4,304,812	3,944,454	3,126,727	2,698,407	2,698,990	2,184,578
Cost Of Revenue	12.0%	5,355,559	4,781,506	4,548,430	4,214,969	4,067,700	4,716,842	4,635,311	5,248,175	5,567,630	5,096,487	4,120,220	3,211,057	4,046,168	1,675,582	1,694,421	1,337,650	494,807	680,081	655,211	712,445	666,341
Gross Profit	16.8%	39,504,289	33,832,405	31,398,483	28,911,366	24,052,016	26,695,627	25,823,187	23,794,662	21,849,254	19,850,712	18,193,391	14,987,055	8,847,385	9,330,181	7,395,362	2,967,162	3,449,647	2,446,646	2,043,196	1,986,545	1,518,237
Operating Expenses	8.5%	41,675,825	38,401,786	36,294,029	31,764,176	34,422,957	33,761,328	38,727,312	36,901,677	35,513,931	32,442,016	34,320,154	26,905,392	41,175,454	29,862,688	10,613,734	4,707,667	3,969,016	3,420,352	2,876,360	2,549,914	2,141,457
S&GA Expenses	3.1%	20,389,121	19,776,797	19,567,903	16,717,645	17,440,781	17,200,859	21,817,966	21,909,825	21,192,126	20,293,935	22,392,179	18,640,731	17,384,395	10,528,833	8,394,331	2,745,882	3,135,526	2,073,016	2,215,913	1,692,178	4,171,394
EBITDA Margin	13.7%	-0.27	-0.32	-0.34	-0.35	-0.36	-0.51	-0.53	-0.56	-0.63	-0.94	-1.26	-1.33	-	-	-	-	-	-	-	-	-
Interest Expenses	-12.8%	622,685	713,766	995,670	264,465	-	132,235	132,236	167,934	153,566	1,824,777	901,910	139,463	714,551	291,096	228,875	793,039	330,194	130,936	129,826	170,194	100,903
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-17,998,716	-14,416,081	-17,028,673	-11,872,886	-33,597,457	-20,823,603	-3,447,247	-2,533,544	-849,562	-1,104,642	-962,990	-733,563	-724,123
EBT Margin	11.0%	-0.29	-0.33	-0.35	-0.36	-0.38	-0.52	-0.55	-0.59	-0.66	-0.98	-1.29	-1.36	-	-	-	-	-	-	-	-	-
Net Income	27.5%	-4,435,984	-6,122,435	-5,891,216	-3,442,473	-11,970,713	-7,281,673	-12,972,961	-13,274,949	-17,877,008	-14,353,375	-17,028,673	-11,872,886	-32,147,255	-20,622,370	-3,447,247	-2,533,544	-604,196	-943,804	-962,990	-733,563	-222,035
Net Income Margin	35.4%	-0.13	-0.20	-0.22	-0.29	-0.38	-0.43	-0.52	-0.60	-0.66	-0.96	-1.27	-1.33	-	-	-	-	-	-	-	-	-
Free Cashflow	435.8%	5,604,298	1,045,953	4,613,761	-2,647,594	-1,956,795	-2,797,548	-10,189,145	-8,358,294	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	43.7%	58.00	41.00	35.00	34.00	26.00	33.00	38.00	26.00	50.00	16.00	24.00	19.00	13.00	5.00	3.00	2.00	3.00	3.00	2.00	3.00	3.00
Current Assets	71.2%	43.00	25.00	20.00	19.00	11.00	13.00	19.00	30.00	45.00	14.00	22.00	18.00	12.00	5.00	2.00	2.00	3.00	2.00	1.00	2.00	2.00
Cash Equivalents	116.8%	33.00	15.00	12.00	12.00	4.00	6.00	12.00	25.00	41.00	9.00	17.00	13.00	9.00	1.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00
Inventory	-27.2%	3.00	4.00	4.00	3.00	4.00	4.00	4.00	1.00	2.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	12.2%	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-
Goodwill	-	-	-	-	-	-	6.00	-	8.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	2.2%	53.00	52.00	46.00	41.00	33.00	30.00	31.00	34.00	24.00	31.00	28.00	16.00	14.00	13.00	8.00	6.00	5.00	3.00	4.00	2.00	2.00
Current Liabilities	6.9%	35.00	33.00	32.00	27.00	31.00	25.00	26.00	26.00	23.00	20.00	19.00	15.00	14.00	9.00	7.00	5.00	4.00	3.00	2.00	2.00	1.00
Long Term Debt	-100.0%	-	19.00	14.00	13.00	-	-	-	-	-	11.00	9.00	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-4.8%	18.00	19.00	14.00	13.00	-	-	-	-	-	11.00	9.00	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-	6.00	-	-	-	-11.87	-	2.00	12.00	22.00	-	-	-	-	-	-	-	-	-	-	0.00	1.00
Retained Earnings	-2.1%	-214	-209	-202	-195	-190	-177	-169	-156	-141	-122	-108	-91.75	-80.15	-47.90	-23.71	-20.24	-16.59	-15.88	-14.94	-12.80	-12.14
Additional Paid-In Capital	10.5%	218	197	187	183	179	177	173	169	165	105	101	92.00	78.00	41.00	19.00	16.00	16.00	15.00	13.00	13.00	13.00
Shares Outstanding	10.4%	38.00	35.00	32.00	32.00	31.00	31.00	31.00	31.00	31.00	26.00	25.00	24.00	23.00	-	-	-	-	-	-	-	-
Minority Interest	29.9%	2.00	2.00	1.00	-0.03	-0.48	-0.80	-1.03	-1.04	-1.03	-1.10	-1.00	-0.77	-2.18	-0.67	-0.47	-0.32	-0.14	-0.10	0.00	-0.18	-0.08
Float	-	-	-	-	-	-	-	50.00	-	-	-	236	-	-	-	83.00	-	-	-	4.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	430.9%	5,714	1,076	4,644	-2,613	-1,969	-2,776	-10,098	-8,091	-5,825	-7,419	-10,733	-9,106	-6,536	-4,498	-1,758	661	159	-547	94.00	546	-416
Share Based Compensation	9.9%	3,646	3,318	2,862	2,664	1,885	3,336	4,041	4,473	4,088	3,111	2,547	2,326	1,757	16,364	439	96.00	207	167	191	155	-
Cashflow From Investing	7.8%	-2,216	-2,403	-2,301	-1,811	-1,771	-2,241	-2,514	-7,378	-1,578	-853	-921	-48.86	-67.55	-53.42	-208	-468	400	-	-	-500	-100
Cashflow From Financing	205.0%	14,361	4,709	-1,961	11,991	1,862	-862	-753	-774	39,285	305	15,663	13,383	14,866	5,132	1,946	-941	-233	1,063	-70.87	16.00	289
Dividend Payments	0.0%	777	777	777	777	777	777	777	777	-	-	-	-	-	-	-	-	-	-	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-420

LFMD Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total revenues, net	$ 152,547,006	$ 119,033,520
Cost of revenues
Total cost of revenues	18,900,464	18,668,028
Gross profit	133,646,542	100,365,492
Expenses
Selling and marketing expenses	76,451,466	78,369,430
General and administrative expenses	51,694,232	46,960,782
Other operating expenses	6,297,321	6,717,795
Customer service expenses	7,632,283	5,033,468
Development costs	6,060,513	2,970,202
Goodwill and intangible asset impairment charges		8,862,596
Change in fair value of contingent consideration		(5,101,000)
Total expenses	148,135,815	143,813,273
Operating loss	(14,489,273)	(43,447,781)
Interest expense, net	(2,596,586)	(1,275,946)
(Loss) gain on debt extinguishment	(325,198)	63,400
Loss from operations before income taxes	(17,411,057)	(44,660,327)
Income tax provision	(428,000)	(360,700)
Net loss	(17,839,057)	(45,021,027)
Net income attributable to non-controlling interest	2,756,935	514,632
Net loss attributable to LifeMD, Inc.	(20,595,992)	(45,535,659)
Preferred stock dividends	(3,106,250)	(3,106,250)
Net loss attributable to LifeMD, Inc. common stockholders	$ (23,702,242)	$ (48,641,909)
Basic loss per share attributable to LifeMD, Inc. common stockholders	$ (0.70)	$ (1.57)
Diluted loss per share attributable to LifeMD, Inc. common stockholders	$ (0.70)	$ (1.57)
Weighted average number of common shares outstanding:
Basic	33,905,155	30,976,455
Diluted	33,905,155	30,976,455
Telehealth Revenue [Member]
Revenues
Total revenues, net	$ 98,152,919	$ 82,649,845
Cost of revenues
Total cost of revenues	17,480,533	17,843,754
WorkSimpli Revenue [Member]
Revenues
Total revenues, net	54,394,087	36,383,675
Cost of revenues
Total cost of revenues	$ 1,419,931	$ 824,274

LFMD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash	$ 33,146,725	$ 3,958,957
Accounts receivable, net	5,277,250	2,834,750
Product deposit	485,850	127,265
Inventory, net	2,759,932	3,703,363
Other current assets	934,510	687,022
Total Current Assets	42,604,267	11,311,357
Non-current Assets
Equipment, net	476,303	476,441
Right of use asset	594,897	1,206,009
Capitalized software, net	11,795,979	8,840,187
Intangible assets, net	3,009,263	3,831,859
Total Non-current Assets	15,876,442	14,354,496
Total Assets	58,480,709	25,665,853
Current Liabilities
Accounts payable	11,084,855	10,106,793
Accrued expenses	13,937,494	12,166,509
Notes payable, net	327,597	2,797,250
Current operating lease liabilities	603,180	756,093
Deferred revenue	8,828,598	5,547,506
Total Current Liabilities	34,781,724	31,374,151
Long-term Liabilities
Long-term debt, net	17,927,727
Noncurrent operating lease liabilities	73,849	574,136
Contingent consideration	131,250	443,750
Purchase price payable		579,319
Total Liabilities	52,914,550	32,971,356
Commitments and contingencies (Note 10)
Mezzanine Equity
Preferred Stock, $0.0001 par value; 5,000,000 shares authorized Series B Convertible Preferred Stock, $0.0001 par value; 5,000 shares authorized, zero and 3,500 shares issued and outstanding, liquidation value approximately, $0 and $1,305 per share as of December 31, 2023 and 2022, respectively		4,565,822
Stockholders’ Equity (Deficit)
Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately, $29.99 and $27.84 per share as of December 31, 2023 and 2022, respectively	140	140
Common Stock, $0.01 par value; 100,000,000 shares authorized, 38,358,641 and 31,552,775 shares issued, 38,255,601 and 31,449,735 outstanding as of December 31, 2023 and 2022, respectively	383,586	315,528
Additional paid-in capital	217,550,583	179,015,250
Accumulated deficit	(214,265,236)	(190,562,994)
Treasury stock, 103,040 and 103,040 shares, at cost, as of December 31, 2023 and 2022, respectively	(163,701)	(163,701)
Total LifeMD, Inc. Stockholders’ Equity (Deficit)	3,505,372	(11,395,777)
Non-controlling interest	2,060,787	(475,548)
Total Stockholders’ Equity (Deficit)	5,566,159	(11,871,325)
Total Liabilities, Mezzanine Equity and Stockholders’ Equity (Deficit)	$ 58,480,709	$ 25,665,853

About LifeMD, Inc.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including urgent and primary care, men's and women's health, and dermatology, chronic care management, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and food and drug administration approved medical device for male and female hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and NavaMD, a female-oriented and tele-dermatology brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. The company sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

CEO	Mr. Justin Schreiber
WEBSITE	https://lifemd.com
INDUSTRY	Healthcare Plans
EMPLOYEES	199

LifeMD, Inc. Frequently Asked Questions

What is the ticker symbol for LifeMD, Inc.? What does LFMD stand for in stocks?

LFMD is the stock ticker symbol of LifeMD, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LifeMD, Inc. (LFMD)?

As of Mon Apr 15 2024, market cap of LifeMD, Inc. is 388.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LFMD stock?

You can check LFMD's fair value in chart for subscribers.

What is the fair value of LFMD stock?

You can check LFMD's fair value in chart for subscribers. The fair value of LifeMD, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of LifeMD, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LFMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is LifeMD, Inc. a good stock to buy?

The fair value guage provides a quick view whether LFMD is over valued or under valued. Whether LifeMD, Inc. is cheap or expensive depends on the assumptions which impact LifeMD, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LFMD.

What is LifeMD, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, LFMD's PE ratio (Price to Earnings) is -19.52 and Price to Sales (PS) ratio is 2.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LFMD PE ratio will change depending on the future growth rate expectations of investors.